The changes offer increased opportunities and flexibility for researchers facing challenges in securing NIH funding in light of recent cutbacks to federal research support. (WASHINGTON—March 20, 2025) The American Society of Hematology (ASH) e...

Expert panel’s findings refute attribution of sudden death to sickle cell trait (WASHINGTON—Jan. 30, 2025) – A systematic literature review found no evidence to support that physical exertion without rhabdomyolysis (muscle breakdo...

ASH Scholar Award Celebrates 40 years of funding early-career hematology researchers   (WASHINGTON, January 17, 2024) — The American Society of Hematology (ASH) announces the 35 recipients of its Scholar Awards for 2025. Now in its 40th ye...

(WASHINGTON, Jan. 7, 2025) — Belinda Avalos, MD, professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer, will serve as president of the American Society of Hematology (ASH) for a year-long term through Decemb...

Association seen regardless of participants’ smoking status and in those with no prior lung disease (WASHINGTON, Dec. 17, 2024) – People exposed to higher concentrations of three types of air pollution over a period of nearly 17 years ha...

Transplant shows no difference in overall or progression-free survival compared with maintenance therapy alone LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Co...

Transplant recipients show better physical, school, and social functioning than those receiving transfusions and medications alone LBA-5: Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Co...

Variants could serve as biomarker to inform prognosis or guide treatment decisions LBA-4: Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (E...

Patients on tafasitamab had a 57% improvement in progression-free survival compared to the control arm LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) (SAN D...

Surveys and focus groups find little integration of DEI principles, yield actionable recommendations (SAN DIEGO, Dec. 9, 2024) — The American Society of Hematology (ASH) leveraged its convening power to launch an initiative for identifying ba...